The Aβ–Tau Inflection Point: A Cellular Point of No Return

The study’s central finding is the discovery of a critical microglial transition at what the researchers call the Aβ–Tau inflection point. This is the critical juncture where amyloid-β pathology first begins to interact with tau pathology, acting as a tipping point that determines whether cognitive decline accelerates or is effectively held in check .

At this inflection point, microglia shift from an early, potentially protective inflammatory state—one rich in signals involving a key receptor called TREM2—into a later, aggressive phenotype that dominates in advanced Alzheimer’s, tightly linked to tau pathology and neurodegeneration . The early protective response helps create a barrier around amyloid plaques, compacting them to limit their toxicity. But once microglia cross this line, they enter a chronic, pro-inflammatory mode that actively drives the disease forward .

The team identified six distinct brain-tissue domains corresponding to different disease stages, with the most dramatic cellular upheaval occurring precisely at the shift from amyloid-β plaque-associated pathology to tau-driven neurodegeneration . It is this microglial state switch—not simply the accumulation of plaques or tangles in isolation—that appears to be the decisive event.

Resilience in Octogenarians: Building Better Walls

The first resilience mechanism emerged from cognitively healthy older adults who carried substantial Alzheimer’s pathology but showed no signs of dementia. In these individuals, microglia did something remarkably effective: they built better walls around amyloid plaques.

Compared to people with clinical dementia, these resilient octogenarians exhibited enhanced microglial dynamics in the immediate vicinity of plaques. They had more microglia surrounding each plaque, more compact plaque cores, and a significant reduction in the accumulation of diffuse, filamentous plaques . The critical consequence was a dramatic drop in tau seeding activity—the toxic spread of tau protein that correlates strongly with neuron death. In fact, tau seeding activity in these resilient brains was comparable to levels found in completely healthy brains .

In essence, their microglia did not need to eliminate amyloid plaques. They contained them. By compacting plaques and reducing their exposed surface area, these immune cells starved the disease cascade of its next step: tau aggregation. Studies in experimental models have confirmed this protective role of TREM2-mediated microglial activation, showing that a loss of TREM2 function dramatically enhances tau seeding and spreading around plaques .

Resilience in Centenarians: Clearing the Decks

Centenarians told a completely different story. Rather than merely containing amyloid, their microglia appeared to be actively destroying it.

The researchers found that microglia derived from centenarians produced strikingly elevated levels of neprilysin, one of the brain’s primary enzymes for degrading amyloid-β . Normally, neprilysin levels decline with age, a process thought to contribute to the gradual buildup of amyloid in the aging brain. But in microglia from select centenarians and "superagers," neprilysin levels were significantly higher than in typical older adults . Functional lab experiments confirmed that these centenarian microglia were substantially more efficient at clearing amyloid, providing a biochemical resilience mechanism that attacks the problem at its very root.

This distinction is biologically profound. Octogenarian resilience is about containment—locking amyloid away so it cannot seed the spread of tau. Centenarian resilience is about clearance—destroying amyloid before it can accumulate to dangerous levels. Both strategies preserve cognition, but they operate through distinct molecular programs. The centenarian mechanism, powered by neprilysin, presents an especially compelling therapeutic target because it suggests that boosting this single enzyme could tip the balance toward amyloid clearance even in an aging brain .

Therapeutic Implications: Reprogramming the Brain’s Guardians

These findings provide a direct biological rationale for therapies that target TREM2, a receptor on microglia that governs their activation state and function. TREM2 is essential for steering microglia toward the protective, plaque-compacting states observed in resilient individuals . The early protective microglial response seen at the Aβ–Tau inflection point is enriched for TREM2-related signaling—the very same pathway that Muna Therapeutics aims to activate with its lead drug candidate .

MNA-001 is an oral small-molecule TREM2 agonist that, in preclinical studies, demonstrated the ability to significantly reduce neurotoxic amyloid burden and reprogram microglia into their protective states . The drug is designed to nudge microglia toward the resilient phenotypes—whether that means enhancing the plaque-compacting response seen in octogenarians or activating amyloid-clearing pathways like neprilysin that dominate in centenarians.

Muna Therapeutics launched the Phase 1 clinical trial of MNA-001 with the first volunteers receiving doses in November 2025 . The study, which is actively recruiting, is evaluating safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamic effects on biomarkers of TREM2 target engagement. Topline data are expected in mid-2026 . In January 2026, the Alzheimer’s Association awarded Muna a $1 million research grant to support the trial and validate translational biomarkers of TREM2 function . Muna’s CEO, Dr. Rita Balice-Gordon, noted that the grant would help shift the treatment paradigm toward early intervention by strengthening the brain’s intrinsic microglial defense mechanisms .

The implications extend far beyond any single drug candidate. The study proposes that the transition from amyloid pathology to tau pathology is not a biological inevitability—it is a modifiable process. Cognitively intact individuals maintain brain health either by avoiding the harmful microglial state transition altogether or by decoupling microglial activation from tau accumulation . A therapy that locks microglia into their early protective mode, or that reactivates amyloid-clearing programs like neprilysin after they have been silenced by age, could intercept Alzheimer’s disease precisely at its tipping point—long before memory loss begins.

Whether MNA-001 or other TREM2-targeting therapies ultimately succeed in the clinic remains an open question, one that only the ongoing trial data can answer. It also remains an active area of investigation to determine precisely which downstream pathways TREM2 agonism engages—containment, clearance, or a combination of both . But the biological logic is now clearer than ever: microglia are not passive witnesses to Alzheimer’s disease. They are the arbiters of its fate.

The Aβ–Tau Inflection Point: A Cellular Point of No Return

The study’s central finding is the discovery of a critical microglial transition at what the researchers call the Aβ–Tau inflection point. This is the critical juncture where amyloid-β pathology first begins to interact with tau pathology, acting as a tipping point that determines whether cognitive decline accelerates or is effectively held in check .

At this inflection point, microglia shift from an early, potentially protective inflammatory state—one rich in signals involving a key receptor called TREM2—into a later, aggressive phenotype that dominates in advanced Alzheimer’s, tightly linked to tau pathology and neurodegeneration . The early protective response helps create a barrier around amyloid plaques, compacting them to limit their toxicity. But once microglia cross this line, they enter a chronic, pro-inflammatory mode that actively drives the disease forward .

The team identified six distinct brain-tissue domains corresponding to different disease stages, with the most dramatic cellular upheaval occurring precisely at the shift from amyloid-β plaque-associated pathology to tau-driven neurodegeneration . It is this microglial state switch—not simply the accumulation of plaques or tangles in isolation—that appears to be the decisive event.

Resilience in Octogenarians: Building Better Walls

The first resilience mechanism emerged from cognitively healthy older adults who carried substantial Alzheimer’s pathology but showed no signs of dementia. In these individuals, microglia did something remarkably effective: they built better walls around amyloid plaques.

Compared to people with clinical dementia, these resilient octogenarians exhibited enhanced microglial dynamics in the immediate vicinity of plaques. They had more microglia surrounding each plaque, more compact plaque cores, and a significant reduction in the accumulation of diffuse, filamentous plaques . The critical consequence was a dramatic drop in tau seeding activity—the toxic spread of tau protein that correlates strongly with neuron death. In fact, tau seeding activity in these resilient brains was comparable to levels found in completely healthy brains .

In essence, their microglia did not need to eliminate amyloid plaques. They contained them. By compacting plaques and reducing their exposed surface area, these immune cells starved the disease cascade of its next step: tau aggregation. Studies in experimental models have confirmed this protective role of TREM2-mediated microglial activation, showing that a loss of TREM2 function dramatically enhances tau seeding and spreading around plaques .

Resilience in Centenarians: Clearing the Decks

Centenarians told a completely different story. Rather than merely containing amyloid, their microglia appeared to be actively destroying it.

The researchers found that microglia derived from centenarians produced strikingly elevated levels of neprilysin, one of the brain’s primary enzymes for degrading amyloid-β . Normally, neprilysin levels decline with age, a process thought to contribute to the gradual buildup of amyloid in the aging brain. But in microglia from select centenarians and "superagers," neprilysin levels were significantly higher than in typical older adults . Functional lab experiments confirmed that these centenarian microglia were substantially more efficient at clearing amyloid, providing a biochemical resilience mechanism that attacks the problem at its very root.

This distinction is biologically profound. Octogenarian resilience is about containment—locking amyloid away so it cannot seed the spread of tau. Centenarian resilience is about clearance—destroying amyloid before it can accumulate to dangerous levels. Both strategies preserve cognition, but they operate through distinct molecular programs. The centenarian mechanism, powered by neprilysin, presents an especially compelling therapeutic target because it suggests that boosting this single enzyme could tip the balance toward amyloid clearance even in an aging brain .

Therapeutic Implications: Reprogramming the Brain’s Guardians

These findings provide a direct biological rationale for therapies that target TREM2, a receptor on microglia that governs their activation state and function. TREM2 is essential for steering microglia toward the protective, plaque-compacting states observed in resilient individuals . The early protective microglial response seen at the Aβ–Tau inflection point is enriched for TREM2-related signaling—the very same pathway that Muna Therapeutics aims to activate with its lead drug candidate .

MNA-001 is an oral small-molecule TREM2 agonist that, in preclinical studies, demonstrated the ability to significantly reduce neurotoxic amyloid burden and reprogram microglia into their protective states . The drug is designed to nudge microglia toward the resilient phenotypes—whether that means enhancing the plaque-compacting response seen in octogenarians or activating amyloid-clearing pathways like neprilysin that dominate in centenarians.

Muna Therapeutics launched the Phase 1 clinical trial of MNA-001 with the first volunteers receiving doses in November 2025 . The study, which is actively recruiting, is evaluating safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamic effects on biomarkers of TREM2 target engagement. Topline data are expected in mid-2026 . In January 2026, the Alzheimer’s Association awarded Muna a $1 million research grant to support the trial and validate translational biomarkers of TREM2 function . Muna’s CEO, Dr. Rita Balice-Gordon, noted that the grant would help shift the treatment paradigm toward early intervention by strengthening the brain’s intrinsic microglial defense mechanisms .

The implications extend far beyond any single drug candidate. The study proposes that the transition from amyloid pathology to tau pathology is not a biological inevitability—it is a modifiable process. Cognitively intact individuals maintain brain health either by avoiding the harmful microglial state transition altogether or by decoupling microglial activation from tau accumulation . A therapy that locks microglia into their early protective mode, or that reactivates amyloid-clearing programs like neprilysin after they have been silenced by age, could intercept Alzheimer’s disease precisely at its tipping point—long before memory loss begins.

Whether MNA-001 or other TREM2-targeting therapies ultimately succeed in the clinic remains an open question, one that only the ongoing trial data can answer. It also remains an active area of investigation to determine precisely which downstream pathways TREM2 agonism engages—containment, clearance, or a combination of both . But the biological logic is now clearer than ever: microglia are not passive witnesses to Alzheimer’s disease. They are the arbiters of its fate.